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Abstract Rationale: Drug challenges in “intact” and p-
chlorophenylalanine (p-CPA)-treated animals can be used
to distinguish agents that act as direct serotonin (5-HT)
agonists from agents that function as 5-HT releasers.
Objectives: The objective of the studywas to investigate the
effect of p-CPA treatment on the capacity of racemic 3,4-
methylenedioxymethamphetamine (MDMA) and its stereo-
isomers to induce the head twitch response, hyperthermia,
and locomotor stimulation in mice. Methods: Pretreat-
ments with either 100 mg/kg p-CPA or equivolume saline
were administered for three consecutive days. The follow-
ing day, mice were either euthanized (to quantify 5-HT
tone), tested with various doses of racemic MDMA or one
of its enantiomers in the head twitch assay, or challenged
with 32 mg/kg racemic MDMA or one of its enantiomers,
while temperature and locomotor activity were monitored
via radiotelemetry. Results: p-CPA reduced cortical 5-HT
turnover by >70% without altering dopamine turnover.
Racemic MDMA did not induce a significant head twitch
response in intact or p-CPA-treated mice. S(+)-MDMA and
R(−)-MDMA elicited similar head twitch curves in intact
mice; p-CPA treatment attenuated this response when
induced by S(+)-MDMA but not when elicited by R(−)-
MDMA. Neither the hyperthermic nor locomotor-stimulant
effects of racemic MDMA were altered by p-CPA treat-
ment. The hyperthermic effects, but not the locomotor-
stimulant effects, of S(+)-MDMA were attenuated in mice
treated with p-CPA. R(−)-MDMA did not alter core tem-
perature or induce significant locomotor stimulation in
intact or p-CPA-treated mice. Conclusions: The effects of
S(+)-MDMA on core temperature and head twitch behavior
are consistent with a mechanism involving 5-HT release,
whereas the effects of R(−)-MDMA on head twitch behav-
ior are consistent with a direct agonist mechanism of action.
The actions of the racemate on core temperature and loco-
motor activity likely involve a combination of 5-HT release
and direct agonism at 5-HT receptors.
Keywords p-CPA . Head twitch response .
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Introduction
Few studies have directly compared the behavioral and phar-
macological effects of 3,4-methylenedioxymethamphet-
amine (MDMA) and its enantiomers, but those that have
typically report differences. For example, Battaglia and
DeSouza (1989) conducted ex vivo radioligand binding
experiments which revealed an asymmetry in the binding
profiles of the MDMA enantiomers, such that S(+)-MDMA
had higher affinity for presynaptic serotonin (5-HT) trans-
porters, whereas R(−)-MDMA had higher affinity for post-
synaptic 5-HT receptors. Similarly, in rat synaptosomes,
S(+)-MDMA was demonstrated to be more potent than
R(−)-MDMA in terms of 5-HT release (Nichols et al.
1982), and later studies of the blockade of 5-HT, dopamine
(DA), and norepinephrine (NE) reuptake revealed a modest
stereoselectivity, with S(+)-MDMAproducing slightly (two-
to fourfold) lower IC50 values for all three monoamines
(Nichols 1986). With regards to in vivo experiments, we
have previously compared the MDMA enantiomers in terms
of their capacity to engender contingent responding in rhe-
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sus monkeys (Fantegrossi et al. 2002), to induce lethality,
hyperthermia, and locomotor stimulation (Fantegrossi et al.
2003), as well as the head twitch response in the mouse
(Fantegrossi et al. 2004a). The results of these studies were
generally consistent with the binding data previously de-
scribed. For example, the reinforcing effects of R(−)-MDMA
in the rhesus monkey were more susceptible to disruption
via the selective 5-HT2A antagonist (+)-(2,3-dimethoxy-
phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol
(M100907, formerly MDL100907) than were those of the
racemate or S(+) enantiomer (Fantegrossi et al. 2002). A
similar pattern of effects was obtained for the lethal effects
of these compounds in singly housed mice (Fantegrossi et
al. 2003). These results, among others, have led us to con-
ceptualize S(+)-MDMA as a 5-HT “releaser,”whereas R(−)-
MDMA may be more akin to a direct 5-HT agonist,
although both isomers overlap in some endpoints and cer-
tainly exert other important pharmacological actions as well
(Battaglia et al. 1988; Acquas et al. 2001; Fischer et al.
2001; Bunzow et al. 2001).
Past research has attempted to behaviorally distinguish
drugs that act as direct 5-HT agonists from drugs that act as
5-HT releasers by comparing the effects of these com-
pounds in “intact” and 5-HT-depleted animals. There are
multiple agents that deplete 5-HT, and the mechanisms of
action for these agents are varied. Correspondingly, results
obtained under different depletion regimens are not nec-
essarily consistent, even when depletion magnitude is equal-
ized (see, for example, Joseph and Appel 1977). And yet,
across several behavioral assays, the effects of 5-HT re-
leasers are attenuated in depleted animals, whereas the
effects of direct agonists are either potentiated (when de-
pletion results in receptor supersensitivity) or not altered
(when depletion does not change receptor sensitivity). De-
pletion in the absence of altered sensitivity to the effects of
5-HT agonists has often been accomplished via repeated
treatment with the 5-HT synthesis inhibitor para-chloro-
phenylalanine (p-CPA). p-CPA acts as an irreversible in-
hibitor of tryptophan hydroxylase, the rate-limiting enzyme
in 5-HT synthesis. A representative and relevant finding in
this regard was reported by Balsara et al. (1986), wherein
mice treated with 100 mg/kg p-CPA for four consecutive
days displayed an attenuated head twitch response when
challenged with the 5-HT releaser fenfluramine, although
the effects of the direct 5-HT agonist ergometrine on head
twitch behavior were not altered in these animals.
Locomotor-stimulant effects of drugs have been strongly
linked to increased dopamine (DA) neurotransmission in
specific brain regions (Wise and Bozarth 1987; Piazza et al.
1991). However, studies investigating the neurochemical
correlates of the locomotor-stimulant effects of racemic
MDMA (Nair and Gudelsky 2004; Bengel et al. 1998) and
S(+)-MDMA (Bankson and Cunningham 2002; Bubar et
al. 2004) in rodents have shown that the dopaminergic
effects of these agents are likely to be indirectly mediated
via serotonergic mechanisms. As such, prior treatment
with p-CPA might be expected to disrupt the locomotor
effects of each compound. Similarly, we have previously
shown that the hyperthermic effects of racemic MDMA
and S(+)-MDMA are sensitive to serotonergic antagonism
(Fantegrossi et al. 2003, 2004a) in the mouse, whereas
others have reported similar findings in the rat (Schmidt
et al. 1990).
Herein we report the effects of racemic MDMA and its
enantiomers on head twitch behavior, locomotor activity,
and hyperthermia in intact and p-CPA-treated mice. The
effects of MDMA on these endpoints have been previously
reported, but the effects of p-CPA treatment on MDMA-
induced head twitches, locomotor stimulation, and hyper-
thermia have not heretofore been studied in the mouse. To
quantify the effects of p-CPA treatment on 5-HT tone, a
group of MDMA-naive mice was euthanized at the end of
the p-CPA regimen. Cortical tissue concentrations of 5-HT,
its major metabolite 5-hydroxyindoleacetic acid (5-HIAA),
DA, and its major metabolites homovanilic acid (HVA) and
dihydroxyphenylacetic acid (DOPAC) were quantified via
high-pressure liquid chromatography (HPLC).
Materials and methods
Animals
Male NIH Swiss mice (Harlan Sprague Dawley Inc., India-
napolis, IN) weighing 20–30 g were housed 12 animals per
44.5×22.3×12.7 cm Plexiglas cage prior to use in drug-
elicited head twitch experiments or surgical implantation of
radiotelemetry probes. Mice were housed in a temperature-
controlled room maintained at an ambient temperature of
22±2°C at 45–50% humidity during all phases of study.
Lights were set to a 12-h light/dark cycle. Animals were fed
with standard rodent chow (Laboratory Rodent Diet #5001,
PMI Feeds, Inc., St. Louis, MO) and water ad libitum until
immediately before testing. Animals were not used in ex-
periments until at least 2 days after arrival in the laboratory.
Each animal was used only once and was sacrificed im-
mediately after use.
Procedure
p-CPA treatment regimen and quantification
of monoamines
Mice were injected intraperitoneally (i.p.) with 100 mg/kg
p-CPA or equivolume saline for three consecutive days. On
the fourth day, mice were tested in one of the assays below
or euthanized so that the extent of 5-HT depletion could be
quantified. For these latter animals, brains were rapidly
removed on ice following cervical dislocation and decap-
itation. Cortex was dissected freehand using blunt curved
microforceps. Tissue samples were immediately placed into
cryovials on dry ice and stored at −70°C until assay.
For tissue determinations, each sample was transferred to
400 μl ice-cold 0.1 N perchloric acid containing N-methyl-
5-HT and 3,4-dihydroxybenzylamine as internal standards
(for indoleamines and catecholamines, respectively). The
tissue was sonicated in this solution and centrifuged at
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23,000×g for 20 min at 4°C. A portion of the supernatant
(50 ml) was removed and analyzed by high-pressure liquid
chromatography (HPLC) to determine the concentration of
DOPAC, HVA, DA, 5-HT, and 5-HIAA. The column em-
ployed was from Bioanalytical Systems (BAS: West Lafa-
yette, IN; Phase II ODS, 3 mM, 100×3.2 mm). The on-line
degassed mobile phase consisted of an 8% solution of
acetonitrile containing 0.6% tetrahydrofuran, 0.1% diethyl-
amine, 0.025 mM ethylenediaminetetraacetic acid, 2.3 mM
1-octane-sulfonic acid, 30 mM sodium citrate, and 13.7 mM
sodium dihydrogen phosphate (final pH 3.1) and was de-
livered at 600 ml/min. Tissue pellets were saved for protein
determination using the DC Protein Assay (Bio-Rad, Her-
cules, CA) with bovine serum albumin as the protein
standard. In this system, optical densities are automatically
converted into milligram units derived from a standard
curve. All protein values are based upon the mean of three
replicates.
Chromatograms were recorded using a DA-5 data ac-
quisition analog to digital interface module coupled to an
LC-4C electrochemical detector (BAS). Postseparation sig-
nals were derived from a 2-mm glassy-carbon working
electrode whose potential was set at 600 mV vs a Ag/Ag Cl
reference. Peak height quantification involved dividing the
peak height of the unknown by that of the internal standard
and referring this ratio to external standards. Because ab-
solute tissue levels reflect both intra- and extrasynaptic
neurochemical concentrations, calculated turnover is pre-
sented as a more accurate reflection of neurochemical con-
tent in each tissue sample. Measurements of turnover are
expressed as the ratio of tissue concentration (in ng/mg pro-
tein) of the primary acidic metabolites (DOPAC and HVA
or 5-HIAA) to the parent amine (DA or 5-HT). Samples
from all animals were processed in parallel on the same day
for each brain region.
Drug-elicited head twitch response
On experimental days, mice were weighed, marked, and
returned to the home cage. Doses were then calculated and
prepared for injection. Individual animals were subse-
quently removed from the home cage, injected i.p. with sa-
line, then placed into a 15.24×25.40×12.70 cm Plexiglas
mouse cage. Tenminutes after the initial injection,micewere
injectedwith various doses of racemicMDMA, S(+)-MDMA,
R(−)-MDMA, or saline and returned to the small observa-
tion cage. Five minutes after this second injection, a camera
mounted above the observation cage began recording be-
havior and continued to do so for 10 min. Videotapes were
later scored for drug-elicited head twitches, here defined as
a rapid rotational jerk of the head that is not contiguous with
any grooming or scratching behaviors, by two blind ob-
servers (e.g., Fantegrossi et al. 2004a). All head twitch
experiments were conducted in the colony room at an am-
bient temperature of 22±2°C, and neither food nor water
was available during the tests.
Core temperature and locomotor activity experiments
Following appropriate anesthetizationwith ketamine (100mg/
kg, i.p.) and xylazine (10 mg/kg, i.p.), the abdominal area
of each mouse was shaved and sanitized with iodine swabs.
A rostral-caudal cut 1.5 cm in length was made with skin
scissors, providing access to the intraperitoneal cavity. A
cylindrical glass-encapsulated radiotelemetry probe (model
ER-4000 E-Mitter, Mini Mitter Co., Inc., Bend, OR, USA)
was then inserted, and the incision was closed using ab-
sorbable 5–0 chromic gut suture material. Surgeries were
carried out at least 7 days before initiation of the p-CPA
depletion regimen, allowing time for incisions to heal and
for the mice to recover normal body weights. Following
surgery, all implanted mice were individually housed in
15.24×25.40×12.70 cm Plexiglas mouse cages for the du-
ration of all temperature and locomotor activity experiments.
Implanted transmitters produced activity- and temperature-
modulated signals which were sent to a receiver (ER-4000
Receiver, Mini Mitter Co., Inc.) underneath each mouse
cage. On experimental days, mice were weighed, marked,
and returned to their individual cages. MDMA doses were
then calculated and prepared for injection. Animals were
subsequently removed from their cage and injected i.p.
with 32 mg/kg racemic, S(+)-, R(−)-MDMA, or equivo-
lume saline and returned to their cage, where temperature
and locomotor activity data were collected at 5-min
intervals and processed simultaneously by the Vital View
data acquisition system (Mini Mitter Co., Inc.) for 3 h. This
dose was chosen based on previous studies (Fantegrossi et
al. 2003) and represents a nonlethal dose that elicits
significant hyperthermia and locomotor stimulation for
racemic and S(+)-MDMA.
Data analysis
For the head twitch experiments, data are presented as mean
±SEM and were compared to values obtained from equi-
volume saline controls (n=6, temperature data not shown)
using one-way ANOVA (one-tailed) and Tukey’s post hoc
tests. Neurochemical data were compared by Student’s
t-tests. All statistical tests were performed using commer-
cially available software, and significance was judged at
P<0.05.
Drugs
Racemic MDMA and its enantiomers were supplied by the
National Institute on Drug Abuse (Research Technology
Branch, Research Triangle Park, NC) and were dissolved in
physiological saline prior to injection. M100907 was syn-
thesized at the Laboratory of Medicinal Chemistry at the
National Institutes of Diabetes, Digestive and Kidney Dis-
orders at the National Institutes of Health (Bethesda, MD)
and dissolved in sterile water and 0.5 N HCl. p-CPA was
purchased from Tocris Cookson (Ellisville, MO) and was
dissolved in 0.01 N NaOH and sterile water to a final pH of
531
8. All injections were administered i.p. in a volume equal to
body weight (g)/100.
Results
p-CPA treatment regimen and quantification of
monoamines
Treatment with p-CPA reduced cortical 5-HT turnover by
greater than 70% (critical t=2.33, 95% confidence interval
for difference of means 0.012–1.98, P<0.05). This effect
was selective for 5-HT systems, as DA turnover was not
altered by p-CPA treatment (Fig. 1).
Drug-elicited head twitch response
Following saline injection, approximately one head twitch
was noted during the 10-min observation period for both
intact and p-CPA-treated animals; there was no statistical
difference between the results obtained with saline across
these groups, so data were collapsed into a single point
(filled triangles, all panels of Fig. 2). Racemic MDMA in-
duced few head twitches in either intact mice or in animals
with reduced 5-HT turnover (Fig. 2, top panel). The maxi-
mal number of twitches elicited by racemic MDMA at all
doses was never different from that observed in saline con-
trol animals for either intact or depleted mice (P>0.05 for
both groups). In contrast to the racemate, S(+)-MDMA in-
duced an inverted U-shaped dose–effect curve across the
dose range tested in both groups of mice (Fig. 2, middle
panel). For intact mice, maximal twitches were elicited at a
dose of 0.32 mg/kg S(+)-MDMA, and this effect was sig-
nificantly greater than that observed in saline controls (p=5,
q=5.79, P<0.05). Importantly, p-CPA treatment shifted the
S(+)-MDMA head twitch curve down and to the right, and
although the shape of the curve was preserved, no dose of S
(+)-MDMA elicited significantly more head twitch behav-
ior than saline in these animals with reduced 5-HT turnover
(P>0.05). Similar to S(+)-MDMA, R(−)-MDMA induced
an inverted U-shaped dose–effect curve in both intact and
p-CPA-treated mice (Fig. 2, bottom panel). Interestingly,
p-CPA treatment did not alter the effects of R(−)-MDMA
on head twitch behavior. In both groups of animals, 1.0 mg/
kg R(−)-MDMA elicited significantly more head twitches
than did saline (p=4, q=9.16 for intact mice; p=4, q=4.89
for mice with reduced 5-HT turnover; P<0.05 for both
groups).
Fig. 1 Neurochemical content in cortex following 3-day treatment
with saline (filled bars) or p-CPA (open bars.) Asterisks indicate
significance (P<0.05) by Student’s t-test. See text for more
information
Fig. 2 Effects of racemic MDMA (top), S(+)-MDMA (middle), and
R(−)-MDMA (bottom) on head twitch behavior in intact (filled sym-
bols) and 5-HT-depleted (open symbols) mice. Each point represents
the mean±SEM (n=6 mice per dose). Abscissae: MDMA dose (mg/
kg, i.p.). Ordinates: Mean head twitches/10 min. Asterisks indicate
significant differences from saline controls (P<0.05) by one-way
ANOVA and Tukey’s post hoc tests
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Core temperature and locomotor activity experiments
Following saline injection, no systematic changes were
observed in core temperature during the observation period;
there was no difference between the results obtained with
saline in intact or p-CPA-treated mice, so data were col-
lapsed across groups and presented as a range of minimum
and maximum temperatures observed over the 180-min
recording period (gray region, all left-hand panels of
Fig. 3). Racemic MDMA rapidly induced an increase in
core temperature in intact mice; by 30-min postinjection,
core temperature had risen 2°C. This hyperthermic effect
gradually recovered, and baseline temperatures were re-
established by 120 min after injection. Prior treatment with
p-CPA did not alter the hyperthermic effects of racemic
MDMA (Fig. 3, top left panel). Similar to the racemate, S
(+)-MDMA induced a hyperthermic response in both groups
of animals tested, but this effect was notably blunted in
mice with reduced 5-HT turnover. Prior treatment with
p-CPA resulted in an attenuation of the magnitude and time
course of S(+)-MDMA-induced hyperthermia (Fig. 3, mid-
dle left panel). In contrast to both the racemate and the S(+)
enantiomer, R(−)-MDMA did not alter core temperature in
either group of mice (Fig. 3, bottom left panel).
Locomotor activity was greatest in the 15-min period im-
mediately following saline injection, but no orderly changes
were observed at later time points. There was no difference
between the locomotor results obtained with saline in intact
or p-CPA-treated mice, so data were collapsed across groups
and are presented as a range of minimum and maximum
activity counts observed over the 180-min recording period
(gray region, all right-hand panels of Fig. 3). Racemic
MDMA elicited a profound and long-lasting locomotor
stimulation in intact mice. This locomotor-stimulant effect
gradually recovered by 180 min after injection. Prior treat-
ment with p-CPA did not alter the locomotor-stimulant
effects of racemic MDMA (Fig. 3, top right panel). S(+)-
MDMA induced a similar, though less pronounced, loco-
motor-stimulant effect in both groups of animals tested.
Prior treatment with p-CPA did not alter the locomotor-
stimulant effects of S(+)-MDMA (Fig. 3, middle right panel).
R(−)-MDMA elicited a modest and brief increase in loco-
motor activity in both groups of mice. This effect was ap-
parent only in the first 15-min period following injection.
Fig. 3 Left panels: Effects of
racemic MDMA (top), S(+)-
MDMA (middle), and R(−)-
MDMA (bottom) on core
temperature in intact (filled
symbols) and 5-HT-depleted
(open symbols) mice. Each point
represents the mean±SEM (n=6
mice per dose). Abscissae: Time
after injection (h). Ordinates:
Core temperature (°C). The gray
region between approximately
37 and 38°C represents the
normal range of rodent core
temperature measured over a
3-h period following equivolume
saline injection. Right panels:
Effects of racemic MDMA (top),
S(+)-MDMA (middle), and R
(−)-MDMA (bottom) on loco-
motor activity in intact (filled
symbols) and 5-HT-depleted
(open symbols) mice. Each point
represents the mean±SEM (n=6
mice per dose). Abscissae: Time
after injection (h). Ordinates:
Activity counts. The gray region
between ∼15 and 35 counts
represents the normal range of
rodent locomotor activity mea-
sured over a 3-h period following
equivolume saline injection
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Prior treatment with p-CPA did not alter the locomotor-
stimulant effects of R(−)-MDMA (Fig. 3, bottom right
panel).
Discussion
In the present studies, prior treatment with p-CPA did not
alter the effects of R(−)-MDMA on head twitch behavior,
and no effects on core temperature or locomotor activity
were observed in intact or treated animals. The results of the
head twitch assay suggest that R(−)-MDMA either func-
tions as a direct 5-HT agonist (at least, in terms of this
particular endpoint) or that this effect is not serotonergically
mediated. The later possibility does not seem likely given
the results of previous antagonist studies where R(−)-
MDMA-induced head twitches were attenuated by two
5-HT2 antagonists (Fantegrossi et al. 2004a). Further
evidence for the mediation of the behavioral effects of
R(−)-MDMA by 5-HT systems comes from rhesus monkey
studies where contingent responding for R(−)-MDMAwas
selectively attenuated by two 5-HT2 antagonists (Fantegrossi
et al. 2002). However, in agreement with previous reports,
R(−)-MDMA has only weak effects on locomotor activity
in the intact mouse and does not appear to induce hyper-
thermia up to doses that result in some lethality (Fantegrossi
et al. 2003). One possible explanation for the general lack of
locomotor-stimulant properties for this compound comes
from in vitro studies of transporter-mediated monoamine
release. One such study has shown that R(−)-MDMA is at
least tenfold less potent than racemic and S(+)-MDMA at
dopamine transporters and approximately five times less
potent than racemic and S(+)-MDMA at norepinephrine
transporters (Setola et al. 2003). Similarly, pilot experi-
ments with the structurally similar direct 5-HT2 agonist
4-iodo-2,5-dimethoxyphenylisopropylamine (DOI) in the
mouse also induced a head twitch response that was in-
sensitive to p-CPA treatment (Fantegrossi et al. 2004b) but
failed to induce locomotor stimulation or hyperthermia at
doses up to 30 times higher than those required to elicit
significant head twitch behavior (unpublished results). Al-
though 5-HT2A/2C agonists have previously been shown to
induce hyperthermia in the rat (Mazzola-Pomieto et al.
1997), this lack of effects on core temperature may be a
property of direct 5-HT2 agonists in mice.
In contrast, the pattern of effects obtained with S(+)-
MDMA seems consistent with this enantiomer acting via
a mechanism dependent on endogenous 5-HT tone. That
prior treatment with p-CPA attenuated head twitch behavior
and hyperthermia suggests that these effects are mediated
by S(+)-MDMA-stimulated 5-HT release. Interestingly, the
locomotor-stimulant effects of S(+)-MDMA were not al-
tered by 5-HT depletion. We have previously reported that
the 5-HT2 antagonist ketanserin, the selective 5-HT2A
antagonist M100907, and the serotonin selective reuptake
inhibitor fluoxetine, at doses that attenuated the locomotor-
stimulant effects of racemic MDMA, potentiated the
locomotor-stimulant effects of S(+)-MDMA (Fantegrossi
et al. 2003). These data, along with the presently reported
differences regarding the effects of p-CPA treatment on the
locomotor-stimulant effects of racemic vs S(+)-MDMA,
are puzzling, as in vitro studies have demonstrated similar
potencies for these compounds at dopamine and nore-
pinephrine transporters (Setola et al. 2003). The pharma-
cological mechanisms underlying S(+)-MDMA-induced
locomotor stimulation in mice clearly deserve further study.
Finally, the cluster of effects seen with racemic MDMA
does not lend itself to a consistent interpretation in terms of
5-HT release and/or direct agonism. We have previously
reported that both S(+)- and R(−)-MDMA induce head
twitches in mice (Fantegrossi et al. 2004a) but present for
the first time evidence that racemic MDMA does not elicit
this behavior in the mouse. Why each of the individual
isomers should elicit this behavior on its own, but not when
administered in combination as racemic MDMA, is not
readily apparent. One possibility has to do with the small
potency difference observed between S(+)-MDMA and
R(−)-MDMA and the biphasic nature of the dose–effect
curves generated. These particular circumstances may re-
sult in reciprocal antagonism across the range of racemic
MDMA doses presently tested. However, this possibility
assumes that the enantiomers are evenly absorbed and dis-
tributed in the mouse following administration of racemic
MDMA, and there is, as yet, no published evidence in this
regard to either support or challenge this interpretation of
the data.
Clearly, the hyperthermic effects of racemic MDMA are
not dependent on endogenous 5-HT tone, implying that
racemicMDMA affects core temperature either by acting as
a direct 5-HT agonist or by impacting some other neuro-
chemical system. This later possibility is unlikely given the
previously described experiments wherein racemic MDMA-
induced hyperthermia in the mouse was blocked by various
serotonergic agents, including ketanserin, M100907, and
fluoxetine (Fantegrossi et al. 2003), as well as the plant-
derived aporphine, nantenine (Fantegrossi et al. 2004a).
However, given that S(+)-MDMA appears to alter core
temperature via a 5-HT release mechanism, and given that
R(−)-MDMA does not affect core temperature at all, it is
difficult to understand why racemic MDMA should elicit
full hyperthermic effects in the p-CPA-treated mouse. It
may be the case that active metabolites of racemic MDMA
are responsible for the effects of this compound on core
temperature. Indeed, similar explanations have been offered
for the neurochemical depleting effects of racemic MDMA
in the rat (Esteban et al. 2001).
In correspondence with the results previously described
for S(+)-MDMA, the locomotor-stimulant effects of ra-
cemicMDMAwere not altered by p-CPA treatment, despite
the pronounced reduction in 5-HT turnover. This effect seems
consistent with the supposition that racemic MDMA exerts
its locomotor-stimulant effects via a direct agonist action, as
we have previously shown that ketanserin, M100907, and
nantenine all attenuated MDMA-induced locomotor activ-
ity at doses that did not alter spontaneous locomotor activity
on their own (Fantegrossi et al. 2003, 2004a). However,
similar effects were also obtained with the 5-HT selective
reuptake inhibitor fluoxetine (Fantegrossi et al. 2003),
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which does not seem consistent with a direct 5-HT agonist
mechanism of action for the locomotor-stimulant effects of
racemic MDMA. As with the hyperthermic effects, the pro-
found locomotor-stimulant effects of racemic MDMA are
difficult to reconcile given the effects of the individual iso-
mers on this endpoint. The dose of racemic MDMA used in
the present studies, 32mg/kg, should be equivalent to 16mg/
kg of each isomer delivered together. The locomotor-stim-
ulant effects of S(+)-MDMA are less than those of the
racemate, and the effects of R(−)-MDMA are milder still.
Therefore, something beyond simple additivity must there-
fore be invoked in order to explain the pronounced effects of
racemic MDMA on locomotor activity in the mouse.
It seems likely that racemic MDMA and its enantiomers
may differ in terms of affinity and efficacy across multiple
receptor systems (although data to support this notion are
few), and it may be plausible to speculate that the stereo-
isomers may, on occasion, interact with each other in com-
plex ways in vivo. Indeed, as we have previously reported,
the in vivo effects of racemic MDMA and its enantiomers
may be distinguished not only in terms of quantitative
differences, but also in terms of qualitative differences
(Fantegrossi et al. 2003). Relatively few studies have di-
rectly compared the MDMA enantiomers across measures,
yet it seems reasonable to suggest that the isomers have
heterogeneous effects that manifest themselves across a
wide range of endpoints, perhaps indicating important dif-
ferences in their underlying pharmacology. In this regard,
the differences herein noted between the effects of racemic
MDMA and its enantiomers in intact and p-CPA-treated
mice are illustrative as stereoselective effects were apparent
in all assays. S(+)-MDMA appears to elicit hyperthermia
and head twitch behavior via a mechanism involving 5-HT
release but stimulates locomotor activity through an action
that is not regulated by endogenous 5-HT tone. R(−)-MDMA
seems to induce head twitches via direct agonist action at
5-HT receptors but has no pronounced effects on core tem-
perature or locomotor activity. Racemic MDMA induces
hyperthermia and locomotor stimulation through a mech-
anism that is not dependent on endogenous 5-HT tone but
does not induce significant head twitch behavior. These
results suggest that the pharmacological actions of MDMA
and its enantiomers are likely to be mediated by different
mechanisms across multiple measures in vivo. We would
caution that any in vivo results obtained with the MDMA
enantiomers may not be particularly informative with
regards to the racemate and vice versa.
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